Toujeo Set For Tresiba Face-Off After Japan Approval
This article was originally published in PharmAsia News
Sanofi's Toujeo is set to compete with Novo's Tresiba in Japan following its approval in this market, while Gilead has also secured a regulatory clearance for its hepatitis C combination Harvoni and Kyowa Kirin for a recombinant antithrombotic preparation.
You may also be interested in...
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.
Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.